(Q37338235)

19 August 2017

1 reference

title

Jumping higher: is it still possible? The ALTTO trial challenge (English)

1 reference

19 August 2017

2

Evandro de Azambuja

0 references

Martine Piccart-Gebhart

series ordinal

5

object named as

Martine Piccart-Gebhart

0 references

Gianluca Tomasello

series ordinal

1

object named as

Gianluca Tomasello

1 reference

19 August 2017

Phuong Dinh

3

1 reference

PubMed ID

19046108

19 August 2017

Natasa Snoj

series ordinal

4

1 reference

19 August 2017

1 December 2008

1 reference

Expert Review of Anticancer Therapy

19 August 2017

1 reference

19 August 2017

8

1 reference

19 August 2017

12

1 reference

19 August 2017

1883-1890

1 reference

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

The emerging role of lapatinib in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Specificity within the EGF family/ErbB receptor family signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.12.1883

10.1586/14737140.8.12.1883

21 January 2018

Identifiers

DOI

1 reference

release_ygr2kuprunfobgqeo77iar5ura

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ygr2kuprunfobgqeo77iar5ura

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19046108

1 reference

PubMed ID

19046108